Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome
Authors' conclusion
ICI triad syndrome is associated with higher overall mortality and shortened median survival times during the first six months after initial ICI therapy, whereas isolated ICI myositis is associated with similar mortality outcomes compared to patients treated with ICI who did not develop myositis.
Study context
- Population
- US veterans treated with an immune checkpoint inhibitor (ICI), June 2011–February 202268 ICI myositis cases
- Participants
- 29,296 veterans
- Exposure
- ICI triad syndrome vs isolated ICI myositis vs ICI-treated patients without myositis
- ICI triad syndromen = 23
- Isolated ICI myositisn = 45
- Outcome
- All-cause mortality
Methodological detailsnational, chart review
- National
- Chart review
Main finding
As reported in the abstract
Median survival
Observational data: associations, not effects.
Further findings
Mortality during 6 months after ICI initiation
Mortality after 6 months from first ICI treatment
- Subsequent mortality trends similar in the three groups
Incidence of ICI-induced myositis
- ICI myositis cases among ICI-treated veterans
- 68 (0.2%)
Original publication
Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome. Arthritis Care Res (Hoboken). Published 18 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →